A prospective randomized wait list control trial of intravenous iron sucrose in older adults with unexplained anemia and serum ferritin 20-200 ng/mL BLOOD CELLS MOLECULES AND DISEASES Price, E., Artz, A. S., Barnhart, H., Sapp, S., Chelune, G., Ershler, W. B., Walston, J. D., Gordeuk, V. R., Berger, N. A., Reuben, D., Prchal, J., Rao, S. V., Roy, C. N., Supiano, M. A., Schrier, S. L., Cohen, H. J. 2014; 53 (4): 221-230


Anemia is common in older persons and is associated with substantial morbidity and mortality. One third of anemic older adults have unexplained anemia of the elderly (UAE). We carried out a randomized, wait list control trial in outpatients with UAE and serum ferritin levels between 20 and 200 ng/mL. Intravenous iron sucrose was given as a 200-mg weekly dose for 5 weeks either immediately after enrollment (immediate intervention group) or following a 12-week wait list period (wait list control group). The primary outcome measure was changed in 6-minute walk test (6MWT) distances from baseline to 12 weeks between the two groups. Hematologic, physical, cognitive, and quality of life parameters were also assessed. The study was terminated early after 19 subjects enrolled. The distance walked in the 6MWT increased a mean 8.05±55.48 m in the immediate intervention group and decreased a mean 11.45±49.46 m in the wait list control group (p=0.443). The hemoglobin increased a mean 0.39±0.46 g/dL in the immediate intervention group and declined a mean 0.39±0.85 g/dL in the wait list control group (p=0.026). Thus, a subgroup of adults with UAE may respond to intravenous iron. Enrollment of subjects into this type of study remains challenging.

View details for DOI 10.1016/j.bcmd.2014.06.003

View details for Web of Science ID 000343527800012

View details for PubMedCentralID PMC4198614